Sugi Predict

Sugi Predict / Compounds / SCHEMBL3232371

SCHEMBL3232371

SCHEMBL3232371

C[C@]12CCC(=O)C=C1CC[C@H]1[C@@H]3CC[C@H](C(=O)CO)[C@@]3(CO)CC(O)[C@@H]12

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C2 P08235 7/20 0.80
▸ SMN1; SMN2 Q16637 6/20 0.80
▸ HIF1A Q16665 6/20 0.80
▸ SHBG P04278 4/20 0.80
▸ SERPINA6 P08185 4/20 0.80
▸ LMNA P02545 4/20 0.80
▸ HSD17B10 Q99714 4/20 0.80
▸ MAPT P10636 3/20 0.80
▸ CYP3A4 P08684 3/20 0.80
▸ NFKB1 P19838 2/20 0.80
▸ MAPK1 P28482 2/20 0.80
▸ BLM P54132 1/20 0.80
▸ CYP2C9 P11712 1/20 0.80
▸ TSHR P16473 1/20 0.80
▸ SLC22A2 O15244 1/20 0.80
▸ SLC22A1 O15245 1/20 0.80
▸ SLC22A3 O75751 1/20 0.80
▸ THPO P40225 1/20 0.80
▸ MTOR P42345 1/20 0.80
▸ SIGMAR1 Q99720 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19327108 1.00 NR3C2 (0.80) NR3C2SMN1; SMN2HIF1ASHBGSERPINA6
SCHEMBL142427 1.00 NR3C2 (0.80) NR3C2SMN1; SMN2HIF1ASHBGSERPINA6
SCHEMBL15763286 1.00 NR3C2 (0.80) NR3C2SMN1; SMN2HIF1ASHBGSERPINA6
SCHEMBL21231249 0.91 HIF1A (0.76) NR3C2SMN1; SMN2HIF1ASHBGSERPINA6
SCHEMBL11211928 0.90 NR3C2 (0.73) NR3C2SMN1; SMN2HIF1ASHBGSERPINA6
SCHEMBL11211930 0.90 NR3C2 (0.73) NR3C2SMN1; SMN2HIF1ASHBGSERPINA6
Epicorticosterone SCHEMBL4380327 0.89 SMN1; SMN2 (1.00) NR3C2SMN1; SMN2HIF1ASHBGSERPINA6
Corticosterone SCHEMBL22612 0.89 SMN1; SMN2 (1.00) NR3C2SMN1; SMN2HIF1ASHBGSERPINA6
Epicorticosterone SCHEMBL21168995 0.89 SMN1; SMN2 (1.00) NR3C2SMN1; SMN2HIF1ASHBGSERPINA6
Epicorticosterone SCHEMBL20058459 0.89 SMN1; SMN2 (1.00) NR3C2SMN1; SMN2HIF1ASHBGSERPINA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0033341-A1 CYTOTOXIC NUCLEOSIDE-CORTICOSTEROID PHOSPHODIESTERS Research Corporation (US) 1981-08-12 — — EP claimed
WO-1981000410-A1 CYTOTOXIC NUCLEOSIDE-CORTICOSTEROID PHOSPHODIESTERS RESEARCH CORP (US) 1981-02-19 — — WO claimed
US-20230372267-A1 AFFINITY MEDICANT CONJUGATE Califia Pharma Inc. (US) 2023-11-23 — — US disclosed
EP-4257186-A2 AFFINITY MEDICANT CONJUGATES AF Chemicals LLC (US) 2023-10-11 — — EP disclosed
US-20230212113-A1 AFFINITY ILLUDOFULVENE CONJUGATES AF Chemicals, LLC, (US) 2023-07-06 — — US disclosed
US-11591295-B2 Affinity illudofulvene conjugates AF CHEMICALS LLC (US) 2023-02-28 — — US disclosed
US-11576876-B2 Affinity Medicant Conjugate AF CHEMICALS, LLC (US) 2023-02-14 — — US disclosed
US-20220213452-A1 CONDITIONALLY ACTIVE HETERODIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-07-07 — — US disclosed
US-20220133649-A1 AFFINITY MEDICANT CONJUGATE Califia Pharma Inc. (US) 2022-05-05 — — US disclosed
US-11241398-B2 Affinity medicant conjugate AF CHEMICALS, LLC (US) 2022-02-08 — — US disclosed
US-20220008361-A1 AFFINITY MEDICANT CONJUGATE Califia Pharma Inc. (US) 2022-01-13 — — US disclosed
US-20180263927-A1 AFFINITY MEDICANT CONJUGATE AF CHEMICALS, LLC (US) 2018-09-20 — — US disclosed
US-20170306303-A1 CONDITIONALLY ACTIVE HETERODIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2017-10-26 — — US disclosed
US-9381178-B2 Affinity medicant conjugate AF CHEMICALS LLC (US) 2016-07-05 — — US disclosed
US-20160015658-A1 AFFINITY MEDICANT CONJUGATE AF CHEMICALS, LLC 2016-01-21 — — US disclosed
US-20150290152-A1 AFFINITY MEDICANT CONJUGATE AF CHEMICALS, LLC 2015-10-15 — — US disclosed
WO-2010015036-A1 BIOLOGICAL APPLICATIONS OF STEROID BINDING DOMAINS HOVENS CHRISTOPHER (AU) 2010-02-11 — — WO disclosed
EP-0033341-A1 CYTOTOXIC NUCLEOSIDE-CORTICOSTEROID PHOSPHODIESTERS Research Corporation (US) 1981-08-12 — — EP disclosed
US-4283394-A ANTICARCINOGENIC AGENTS RESEARCH CORPORATION (US) 1981-08-11 — — US disclosed
WO-1981000410-A1 CYTOTOXIC NUCLEOSIDE-CORTICOSTEROID PHOSPHODIESTERS RESEARCH CORP (US) 1981-02-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212113-A1 AFFINITY ILLUDOFULVENE CONJUGATES OGFR, TNFSF11, FCER2 NR3C2 3284/4885SMN1; SMN2 2596/4885HIF1A 1272/4885
US-20160015658-A1 AFFINITY MEDICANT CONJUGATE FCER2, HDGF, FCGR2A NR3C2 606/4885SMN1; SMN2 3267/4885HIF1A 2191/4885
US-20230372267-A1 AFFINITY MEDICANT CONJUGATE FCER2, HDGF, FCGR2A NR3C2 606/4885SMN1; SMN2 3267/4885HIF1A 2191/4885
US-20220133649-A1 AFFINITY MEDICANT CONJUGATE FCER2, HDGF, FCGR2A NR3C2 606/4885SMN1; SMN2 3267/4885HIF1A 2191/4885
US-20150290152-A1 AFFINITY MEDICANT CONJUGATE FCER2, HDGF, FCGR2A NR3C2 606/4885SMN1; SMN2 3267/4885HIF1A 2191/4885
US-11591295-B2 Affinity illudofulvene conjugates OGFR, TNFSF11, FCER2 NR3C2 3284/4885SMN1; SMN2 2596/4885HIF1A 1272/4885
US-20220213452-A1 CONDITIONALLY ACTIVE HETERODIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF CPB2, AGBL2, IAPP NR3C2 4062/4885SMN1; SMN2 2892/4885HIF1A 2779/4885
US-20170306303-A1 CONDITIONALLY ACTIVE HETERODIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF CPB2, AGBL2, IAPP NR3C2 4062/4885SMN1; SMN2 2892/4885HIF1A 2779/4885
US-11576876-B2 Affinity Medicant Conjugate FCER2, HDGF, FCGR2A NR3C2 606/4885SMN1; SMN2 3267/4885HIF1A 2191/4885
US-20180263927-A1 AFFINITY MEDICANT CONJUGATE FCER2, HDGF, FCGR2A NR3C2 606/4885SMN1; SMN2 3267/4885HIF1A 2191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.